Side-by-side comparison

ABT vs SYK — Side-by-side comparison

ABT screens cheaper on EV/FCF, SYK has the higher ROIC, SYK has grown revenue faster over five years, and SYK has the cleaner balance sheet by net debt / EBITDA.

ABT

Abbott Labs

Price

$87.41

Market cap

$230.7B

Day %

N/A

SYK

Stryker Corp.

Price

$316.48

Market cap

$145.6B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


ABT Target	Abbott Labs	$230.7B	23.5x	31.8x	10.0%	5.1%	16.7%	N/A	0.5x	N/A
SYK	Stryker Corp.	$145.6B	37.7x	33.0x	14.5%	11.8%	17.1%	64.0%	-0.6x	N/A

ABT implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

31.8x

FCF yield

3.2%

5Y rev CAGR

5.1%

SYK implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

33.0x

FCF yield

2.9%

5Y rev CAGR

11.8%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABT.

Grade C

/ 100

Quality Radar0 – 20 per axis

Quality Scorecard

Build-time composite score for SYK.

Grade B

/ 100

Quality Radar0 – 20 per axis